Aslan lists on NASDAQ

Aslan Pharmaceuticals Ltd. (TPEx:6497; NASDAQ:ASLN) raised $42.2 million through the sale of 6 million shares at $7.03 in a NASDAQ listing underwritten by Leerink, Piper Jaffray, BTIG, H.C. Wainwright and CLSA. The price values Alsan at $235.7 million.

Singapore-based Aslan is developing a pipeline of candidates for cancers that are prevalent in Asia and target Orphan indications in the U.S. and Europe. Its lead program, varlitinib (ASLAN001), is an inhibitor of EGFR (ErbB1; HER1), HER2 and HER4. Aslan expects top-line data next year from the Phase II/III TreeTopp trial of varlitinib to treat biliary tract cancer. Aslan also anticipates data next half from a Phase II trial of the candidate to treat gastric cancer...